EMEA guidelines on similar biologicals
The European Medicines Agency (EMEA) has published a set of five final guidelines on similar biological medicinal products, aimed at helping the pharmaceutical industry in the development of this new type of application for marketing authorization.
A general regulatory guideline on similar biologicals was finalized in September 2005 and the ones published this month gives guidance on quality, non-clinical and clinical issues. The product class specific annexes to the latter two give guidance for certain groups of medicines: those containing insulin, somatropin and recombinant granulocyte-colony stimulating factor, and come into effect from June 1. In addition, a further class specific annex for medicines containing epoetin will also be available shortly, says the EMEA.
...and two concept papers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze